Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.80+0.10 (+0.60%)
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Xeris Biopharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Xeris Biopharma's total debt was $252.59M at Jun 30, 2026. For fiscal 2025 it was $220.34M, down 5.1% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.34M | -5.1% |
| FY2024 | Dec 31, 2024 | $232.11M | +21.6% |
| FY2023 | Dec 31, 2023 | $190.93M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $252.59M | +15.5% |
| Q1 FY2026 | Mar 31, 2026 | $221.22M | -3.7% |
| Q4 FY2025 | Dec 31, 2025 | $220.34M | -5.1% |
| Q3 FY2025 | Sep 30, 2025 | $219.47M | +1357.6% |
| Q2 FY2025 | Jun 30, 2025 | $218.63M | +14.5% |
| Q1 FY2025 | Mar 31, 2025 | $229.76M | – |
| Q4 FY2024 | Dec 31, 2024 | $232.11M | – |
| Q3 FY2024 | Sep 30, 2024 | $15.06M | – |
| Q4 FY2023 | Dec 31, 2023 | $190.93M | – |
See a number that looks wrong?